{"name":"Mirati Therapeutics Inc.","slug":"mirati-therapeutics-inc","ticker":"","exchange":"","domain":"mirati.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":12436000,"revenueGrowth":-82.7,"grossMargin":0,"rdSpend":531627000,"netIncome":-740867000,"cash":235260000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Enfortumab Vedotin-Ejfv","genericName":"Enfortumab Vedotin-Ejfv","slug":"enfortumab-vedotin-ejfv","indication":"Locally advanced or metastatic urothelial cancer","status":"phase_2"},{"name":"MRTX849","genericName":"MRTX849","slug":"mrtx849","indication":"Non-small cell lung cancer with KRAS G12C mutation","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Sitravatinib 50 mg","genericName":"Sitravatinib 50 mg","slug":"sitravatinib-50-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Enfortumab Vedotin-Ejfv","genericName":"Enfortumab Vedotin-Ejfv","slug":"enfortumab-vedotin-ejfv","phase":"phase_2","mechanism":"Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4.","indications":["Locally advanced or metastatic urothelial cancer","Locally advanced or metastatic urothelial cancer with disease progression during or following platinum-containing chemotherapy, or within 12 months of receiving previous adjuvant chemotherapy in the neoadjuvant or adjuvant setting"],"catalyst":""},{"name":"MRTX849","genericName":"MRTX849","slug":"mrtx849","phase":"phase_3","mechanism":"MRTX849 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.","indications":["Non-small cell lung cancer with KRAS G12C mutation","Colorectal cancer with KRAS G12C mutation","Pancreatic cancer with KRAS G12C mutation"],"catalyst":""},{"name":"Sitravatinib 50 mg","genericName":"Sitravatinib 50 mg","slug":"sitravatinib-50-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOS1d5X2ZDZnQ4dUxnSGdKN0lWTjdHX2JzWWdKMk1vSmczWER5XzVHM0VJX2dpVFBEUk1aYldlQkVwSlZCMHl5UUlUQU15U1ZObUtvLW5JNWVLN1VBZEZtNVB6NWZNQU9yVk5obnpPN3dsQlJMcmItaHFoM29pSVhaeFpSbEFyZjdwSUt2OTNlcHY1eXBxaHFxTFZqMjhfMkktUVhweFZpWktGWW9tclBmT0ZacFhKODlVcVMtd3VZQ09LSVFjM2FfcTlreWlHYjdac1p5czJQRC0zbzZ6Ty1aRW9MWEpHSzhBNlBvZks0d3BQbmV4WFE?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQTlYaEZqN3JLelZ3dHFJaEZTbDZMdVFXQWxvdThGbl9PMk1EZmlGcUl0ZnlQTnF2ZDlYN2xsMmdmcDFPaEhsNFVPSWZhRVB3aDF6MVBXY1d5RmJwT0ozWi1DMkJMYU1UTXRoV2FBaWpib25tZ29tR3NXUXN4TVp0ZFJIUW42RTZiQUl1US16N3UyUlQwNmZsUGhsYnpvYjh4ZEdkLTZlckpiOVhjZmxYSnRtOHhVTWFRdVJmWWZMUWxYOGVJVlJxX2R2dUZJRUQ3SHhNMA?oc=5","date":"2025-12-01","type":"pipeline","source":"The ASCO Post","summary":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups - The ASCO Post","headline":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZzhEX2pQRFZaYW85aUJLNGVtaXJtdmJMYkdCUEctdWJaSkFlTWFMMS15azZEdVVIOGVpc2g2STlTaWJOQ1NfSm9XTHA4SXlYQU04SXNEUDNhUmZ1WmRIRW1RejJSQkR1ekdZOVEtQnpXeXpCTnBMZl9ydmJLWE1Ic1NidDJjUmFGaUpnSGxFUnBnYmQtRDF1eU14Z2xlU25nSWM0?oc=5","date":"2025-10-30","type":"pipeline","source":"Fierce Biotech","summary":"BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fierce Biotech","headline":"BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQVWhWeWdSeXREb2Q2Z2otNXVDN3p1WWxOdm12bTBOZU9Wa1NYeC11a0pvUWhGek1BOTdBZmdzVEhfbTNtRjdOWF9USTh2YWY3RzY1bGFZNzZwLV9STnRGSm9uS1l3dWhSX1hzdGpIWWx1S29MbHNCcjFqVncxT1llVlU2U3Q5b1RPcHlUOFVzdkZBNW5wNVVDTVhFcTNBMjB6aWhkbWJEc0NUSk02cFBMaW9pcXFXUUtZcUpNRkRpVXNWaDBSbHRtajRaay1NTTBhM283dGVEWQ?oc=5","date":"2024-11-07","type":"trial","source":"BioSpace","summary":"Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - BioSpace","headline":"Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth","sentiment":"neutral"},{"date":"2024-02-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-02-09","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: MS INITIAL","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-01-31","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQZE9VWVlOa2ZhOFVOaF84Yk15Rk9XbHY1MUJiRHhwZWl4NWMtRTMyajhMT0l1U0JGeDJEQlJjaEVobXlWNDh5ZVFkWXNNeHpBcm4yUWxmT3VMenRoSzVDSUNDRXFfcFdvX2J0LVByTjhqVzJycDNWVDh0QmNjdUNoZHRUZXNadk5hUzR2LUc0dEc?oc=5","date":"2024-01-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"Bristol Myers Squibb concludes Mirati acquisition for $5.8bn - Pharmaceutical Technology","headline":"Bristol Myers Squibb concludes Mirati acquisition for $5.8bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTDFzX1VzR3JObjJiakZMQmc2cW5BNXRuVlFmNmlPTVJjcG50bi1iYzJicmZKRjh5bWZ6WVJyUFFGQklPLU5HajhqVGJNVkNDaWJLeXFhS2Faa2NTZl9TXzhkQ2lQa18xWlR6bGExcUQ0N1NZX3Z6Zjc1OEgxdjZpaHJxYXNuY1VQa2ZDRG5VR1ZySUhlZmhsSg?oc=5","date":"2023-10-16","type":"deal","source":"San Diego Business Journal","summary":"Bristol Myers Squibb Buys Mirati for $4.8B - San Diego Business Journal","headline":"Bristol Myers Squibb Buys Mirati for $4.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOZkh3V1JkX0hjZzlVaVpEb2ZuRzZYemRpR2J2VmVaeUZnSVVRRUo5bU4wQWRycERraG1CeUNHRHVKZ1FtRnVjaXNVcy00eVEzVGVacUh4a2ZwMGpJdk42X05BT2NhcHg4UExuV2J5Vm5ibFBaWEVCMDQ4M0Z0YVNYcTRhRUNDWnFxZkdVOERFYl83YjZ1NFVsRzNaT0lvb0E3OW9HellHc0E4ZERuRkhQRXl3?oc=5","date":"2023-10-09","type":"deal","source":"Fierce Pharma","summary":"Bristol Myers Squibb buys Mirati for up to $5.8B as I-O giant branches out into targeted therapy for cancer - Fierce Pharma","headline":"Bristol Myers Squibb buys Mirati for up to $5.8B as I-O giant branches out into targeted therapy for cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPNDdCQ3BvSUdncklOcF9rQXcyemZVWjEtZGpQVElZRXI0eDNicWIzY0E2VzlQV05GWmI5cGx6NjkxZGtCUkI0bU5HSEVVd2tObTA3OEJVQjg5Rk5zRUNJak1iMHV3OGZaRVZvUDJ2ZU1KTlJRY2drOEZZcXQ0VnVVYTBXcGw?oc=5","date":"2023-10-09","type":"deal","source":"Yahoo Finance","summary":"Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B - Yahoo Finance","headline":"Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNdDNxTy16MTlENmFtT3poT1JkYWo2anlaNnBNNzI5MERLUmMyRG02SkdtbE9RbFo5ZmZqVy1wbV9IejNPZVQ4X1FHeVJLck55a1VENnZRMW5uSXlfNER6YXd4VWs3ajNQRFdxOFljX2ctSkU0UXBYY1F3eTZKVHpvYTJOUE1OeG1PR3ZhTUh4TWVKc2ZiRkprYUFVdFF4eGF2V1djblhXRzI3RlE?oc=5","date":"2023-10-09","type":"deal","source":"Bloomberg.com","summary":"Bristol Myers (BMY) to Buy Mirati Therapeutics (MRTX) for $4.8 Billion - Bloomberg.com","headline":"Bristol Myers (BMY) to Buy Mirati Therapeutics (MRTX) for $4.8 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTHJ5RHpXS0VrLUc0RlZpeFd2UjNLX1ZEUHM2U2t4Zmk1ZWdpSUxMWDlVN2poT1lINHNvSF9oSXh4ZjhKdDFmeHdrOFZZaFBhSmFJdG5mTzhudzZaZzBFTm5kNUsyQ1FjNW5pNllzaTk4NUxScWF0TWQwaHpaa2FvZkhBYWJmTDFqZ1VWV01QZWcyRDVSV0huOA?oc=5","date":"2023-10-08","type":"deal","source":"BioPharma Dive","summary":"Bristol Myers to buy KRAS cancer drug developer Mirati for $4.8B - BioPharma Dive","headline":"Bristol Myers to buy KRAS cancer drug developer Mirati for $4.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQR2pKVXA0N2hGYV9DMkNfSXlfaFJtTlREWTU3bUR2UGJjTG12SlpsOWVmT2pYMlg1N09EOU9wUXRyUGpicDJCa015TFZ3RXBoNllBcWNJV0xEeVhDZTB3YWN5U190Qzl2X3l4N052RVdiSlZiYjBXRi11eXpNNTU4MEpoMVRzLTI4dUFCWjN4ZmlfNjQwSjE3MWl0cXhHYjNKVG9rLXJnOFJyZ25iaXRoY1JZWFJNZw?oc=5","date":"2023-10-06","type":"pipeline","source":"Bloomberg.com","summary":"Sanofi Is Exploring Acquisition of Cancer Drugmaker Mirati - Bloomberg.com","headline":"Sanofi Is Exploring Acquisition of Cancer Drugmaker Mirati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPT2NlSC1KN3lGQUJTelU3ZGFZR0lsLXFpS1NUdlRGQzJzVk1HQmRaRGQ5QmlUWWhHNUkxQkJXdXU4YTlOODBuZE5pVlN3dlpxdHBtWllaV0RDb2FPcThXcGhGMVBjaXVqd1ZFeHhXMkdEOXNsRXE0QXQ4ZFZtc1N5bTZTX3JTZERMemljRGJrVjhhTWdpQkpXSjBydHhTTmh2Y2J0VTVUVFdxZUxBSld0al9kVkduRUhtaXZ6YnpfU3FmeFpWdlFyamRMNThLTFlsTDBn?oc=5","date":"2023-08-23","type":"pipeline","source":"PR Newswire","summary":"Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer - PR Newswire","headline":"Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":1,"phase_1":1},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":12436000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":12436000,"period":"2022-12-31"},{"value":72092000,"period":"2021-12-31"},{"value":71793000,"period":"2021-09-30"},{"value":0,"period":"2021-06-30"},{"value":0,"period":"2021-03-31"},{"value":13398000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":531627000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-740867000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":235260000,"cashHistory":[],"totalAssets":1202647000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}